Shire¥¸52»õ¬ü¤¸ÁÊNPS
ÂXªvÀø¨u¨£¯e¯fÃĪ«²Õ¦X
¡i©ú³ø±M°T¡j·Rº¸Äõ»sÃĶ°¹ÎShire(¥N¸¹SHPG)¬Q¤Ñ«Å¥¬¡M¥¸52»õ¬ü¤¸²{ª÷¦¬Áʬü°ê¦P·~NPS Pharmaceuticals(¥N¸¹NPSP)¡MÂÇ¥HÂX¤j¨äªvÀø¨u¨£¯e¯fÃĪ«²Õ¦X¡C
Á`³¡¦ì©ó³£¬fªLªºShire±N¥H¨CªÑ46¬ü¤¸²{ª÷¦¬ÁÊNPS¡M¦¬ÁÊ»ù¤ñNPS¦b¤W©P¤ªº¦¬¥«»ù°ª¥X9.8¢H¡CY¥H¥h¦~12¤ë16¤é¦¬ÁÊ®ø®§¥¼ªnº|®Éªº¦¬¥«»ù¬Û¤ñ¡M·¸»ù°ª¹F51¢H¡C
¦¬ÁʤwÀò¨â¶¡¤½¥q¸³¨Æ§½§åã
¨â¶¡¤½¥q¸³¨Æ§½¤w¸g§åã¤F³o¶µ¦¬ÁÊ¡M¥æ©ö¹w®Æ¦b¤µ¦~º©u«×§¹¦¨¡CShire¹w®ÆNPS±N¦b2016¦~«×¼W²K¨ä¬Õ§Q¡C
¥H·s¿A¦èBedminster¬°°ò¦aªºNPS¡M±N§UShire¶i¤@¨B¦V¨u¦³¯e¯f¨Ò¦pG¸z»P¤º¤Àªc¥¢½Õµ¥»â°ìÂX®i¡C
NPS±N¦b1¤ë24¤éª¾±x¡M¨ä·s¬ãµoªºÃĪ«Natpara¯à§_Àò±o¬ü°ê¹ª«¤ÎÃĪ«ºÞ²z§½§åã¡CNatpara¥Î¥HªvÀø¥Òª¬®Ç¸¢¥\¯à´î°h¯g¡M¬O¤@ºØ¨u¨£ªº¤º¤Àªc¯e¯f¡C¦pÀò§åã¡M±N¬O²Ä¤@°¦ªvÀø¦¹ºØ¥i¯àP©R¯e¯fªºÃĪ«¡C¡@
AbbVie¥h¦~10¤ë©ñ±ó¦¬ÁÊShire
Shire¦æ¬FÁ`µôFlemming Ornskov©ó¥h¦~11¤ë®É´¿¹ï¥~³zÅS¡M¦bAbbVie(¥N¸¹ABBV)©ó¥h¦~10¤ë¨M©w©ñ±ó¦¬ÁÊShire«e¡M¤w¸g«·s¼fµø¦hÓ¦¬Áʾ÷·|¡C
AbbVieì¨Óp¹º¥H520»õ¬ü¤¸¦¬ÁÊShire¡M¥H¹Ï§Q¥Î·Rº¸Äõ¸û§C¥ø·~µ|²v¡M¦ý¦b¶ø¤Ú°¨¬F©²¤£¥D±i¬ü°ê¥ø·~³o¼Ë°µ«á¡MAbbVie²×©ó¨ú®ø¥æ©ö¡MShireÀò±o16»õ¬ü¤¸©î¥ë¶O¡C
´^³Õ¥h¦~12¤ë¥÷´¿¤Þz®ø®§¤H¤h³ø¹D¡MShire¥¿¦b¦Ò¼{¦¬ÁÊNPS¡C
¬°¨DÄ~Äò«O¦³¸û§Cµ|²v¡MShire¤´¥H·Rº¸Äõ¬°Á`³¡¡MOrnskov©M¨ä¥L°ª¼hºÞ²z¤Hû±N¦b³Â¬ÙLexington¤u§@¡C
Ornskovªí¥Ü¡M¦¬ÁÊNPS«á¡A¯à°÷±À°ÊShire¼Wªø¡M¬OÁÚ¶i¦¨¬°¤@®a¨ã»â¥ý¥Íª«§Þ³N¤½¥qªºÅãµÛ¤@¨B¡C
¦X¨Öª§¨úÂùĹ
NPS¦æ¬FÁ`µôFrancois Nader«ü¥X¡M¨â®a¤½¥q¦X¨Ö¡M°£¤F±À°ÊªÑªF»ùÈ¥~¡M¨Ã¥i¥[±jªA°È¥þ²y±w¦³¨u¨£¯e¯fªº¯f¤H¡C
Shire´¿·Q¦¬ÁÊCubist Pharmaceuticals¡M¦ý³Ì«á³QÀq§J(¥N¸¹MRK))¥H84»õ¬ü¤¸¹Ü±o¡C
NPSÁÙ¥X°âGattex¡M³o¬OªvÀø¦¨¤Hµu¸zºî¦X¼x¨u¦³¯fªºÃĪ«¡M¤ÀªRû¦ôp¸ÓÃĪ«¦b2016¦~¤º¡M±N¥i³Ð³y¶W¹L3»õ¬ü¤¸¾P°â¦¬¤J¡CGattex±N¥i»PShire²{¦³ªvÀøG¸z¯fÃĪ«¬Û¤¬¬Û©Óµo®i¡C
¤W©P¤NPS¦b¯Ç¥«¦¬³ø41.91¬ü¤¸¡M¤U¶^1.01¬ü¤¸¡M©Î2.35¬ü¤¸¡M¦¬¥««á·L¤É0.11¬ü¤¸¡M©Î0.26¢H¡M¦Ü42.02¬ü¤¸¡C
Shireªº¬ü°ê¹w°UÃҨ馬³ø217.49¬ü¤¸¡M¤W¤É3.40¬ü¤¸¡M©Î1.59¢H¡M¦¬¥««á¤U¶^0.03¬ü¤¸¡M©Î0.01¢H¡M¦Ü217.46¬ü¤¸¡C
¨C¤éªÑ¥«°òª÷¦æ±¡½ÐÂIÀ»³o¸ÌÀò±o¸Ô²Ó¸ê°T¡C